We are a clinical stage immune cell therapy biopharmaceutical company in China focused on the innovation, development and clinical translation of cellular immunotherapies mainly for solid tumors. Leveraging multiple proprietary cell engineering platforms, we are currently advancing eight pipelines, investigating the emerging field of immune cell therapies across multiple cancer types.

Cellular immunotherapies have shown revolutionary and potentially curative promise in hematologic malignancies and are now being actively explored as a transformative treatment for solid tumors. Our product pipelines target tumor-associated antigens such as ALPP, IL-13Rα2, GPC3, DLL3, NY-ESO-1 and LMP2, which are highly expressed in a range of solid tumors, including but not limited to ovarian cancer, endometrial cancer, glioblastoma, liver cancer, lung cancer, sarcoma and nasopharyngeal cancer.

To address the unique challenges of cellular immunotherapy development, we have established an integrated approach for the development of our product candidates, encompassing end-to-end in-house capabilities across R&D, manufacturing and clinical translation. Our approach is designed to achieve rapid iteration and optimization of both CAR-T and TCR-T candidates, incorporating embedded workflows and proprietary technologies. By collaborating closely with internationally renowned scientists, oncologists and qualified hospitals, we strive to ensure that our clinical trials meet the standards promulgated by relevant health authorities and are strategically positioned to facilitate future approvals, partnerships and commercialization.

To support our R&D roadmap and clinical translation, we have established multiple R&D centers and manufacturing facilities in the U.S. and China. These facilities provide the foundation for efficient product development, paving the way for our future advancements in the cellular immunotherapy field.